Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Wiley Interdiscip Rev RNA. 2018 Apr 25;9(4):e1476. doi: 10.1002/wrna.1476

Figure 3. Recurrent splicing-factor alterations detected in human tumors.

Figure 3

Genomic alterations including expression changes and recurrent somatic mutations in splicing factors detected in more than 2% of tumors in several cohorts of patients, including TCGA data, are indicated per tumor type. Splicing-factor upregulation are depicted in red, downregulation in blue, and somatic mutations in green (See legend for details). Several splicing factors can be found both upregulated and downregulated in tumors of the same tissue, suggesting that distinct splicing-factor genomic alterations are associated with distinct tumor subtypes within the same tissue. AML: acute myeloid leukemia; AML/MDS: acute myeloid leukemia myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia; HN: head and neck; MDS w/o RS: myelodysplastic syndrome without ringed sideroblasts; RARS/RCMD: refractory anemia with ringed sideroblasts and refractory cytopenia with multilineage dysplasia and ringed sideroblasts; MPN: myeloproliferative neoplasm. See references in text.